Jayanthi Chandar

Dr. Jayanthi Chandar

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2011 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
OMOmer Mansoor
Omer Mansoor
JCJayanthi Chandar
Jayanthi Chandar
MRMaria M. Rodriguez
Maria M. Rodriguez
CACarolyn L. Abitbol
Carolyn L. Abitbol
WSWacharee Seeherunvong
Wacharee Seeherunvong
GZGaston Zilleruelo
Gaston Zilleruelo

13 January 2020 in Pediatric Nephrology
Verified
Journal Article
Closed access
JCJayanthi Chandar
Jayanthi Chandar
LCLinda Chen
Linda Chen
MDMarissa Defreitas
Marissa Defreitas
GCGaetano Ciancio
Gaetano Ciancio
GBGeorge Burke
George Burke

1 October 2006 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
AOAli Mirza Onder
Ali Mirza Onder
JCJayanthi Chandar
Jayanthi Chandar
SCSheila Coakley
Sheila Coakley
CACarolyn Abitbol
Carolyn Abitbol
BMBrenda Montane
Brenda Montane
GZGaston Zilleruelo
Gaston Zilleruelo

8 March 2007 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
JCJayanthi Chandar
Jayanthi Chandar
CACarolyn Abitbol
Carolyn Abitbol
BMBrenda Montané
Brenda Montané
GZGastón Zilleruelo
Gastón Zilleruelo
Background. The traditional management of children with proteinuric kidney disease is treatment with high dose steroids regardless of comorbid conditions such as obesity. This study evaluated the effect of angiotensin blockade (AB) alone as the sole management of children with non-diabetic proteinuric kidney disease.

1 September 2007 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
AOAli Mirza Onder
Ali Mirza Onder
JCJayanthi Chandar
Jayanthi Chandar
MSMarie Saint-Vil
Marie Saint-Vil
GLGabriela Lopez-Mitnik
Gabriela Lopez-Mitnik
CACarolyn L. Abitbol
Carolyn L. Abitbol
GZGaston Zilleruelo
Gaston Zilleruelo

10 March 2008 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
AOAli Mirza Onder
Ali Mirza Onder
JCJayanthi Chandar
Jayanthi Chandar
NSNancy Simon
Nancy Simon
RDRosa Diaz
Rosa Diaz
ONObioma Nwobi
Obioma Nwobi
GZGaston Zilleruelo
Gaston Zilleruelo
Background. An accepted pathogenesis of catheter-related bacteraemia (CRB) is the seeding of microorganisms from the intraluminal biofilm of central venous catheters. Antibiotic locks (ABL) are solutions containing high concentrations of antimicrobials with or without anticoagulants that aim to destroy the biofilm. Methods. In this study, two different ABL solutions, tissue plasminogen activator (TPA)-based and heparin-based ABL, used in conjunction with systemic antibiotics, were prospectively compared in the treatment of CRB. Results. A total of 42 children on chronic haemodialysis with 11 016 catheter-days were observed for signs and symptoms of CRB over a period of 10 months. Twenty-four CRBs were diagnosed in 18 children (2.2 CRB/1000 catheter-days) and were treated with the protocol. Symptoms of CRB resolved in 83% within 48 h of treatment. None of the infected catheters required early emergent exchange or removal for poorly controlled CRB. Six children had recurrence of CRB within 6 weeks, of which four required catheter exchange. There was no specific microorganism or type of CRB that predisposed to higher recurrence rates. The mean infection-free survival of the catheters following TPA–ABL treatment was shorter than that following heparin–ABL treatment, but was not statistically significant by the log-rank test (126.8 ± 81.6 days versus 154.5 ± 70.4 days). Conclusion. Both TPA–ABL and heparin–ABL used in conjunction with systemic antibiotics can effectively clear CRB without significant late recurrence at 6 weeks. Early use of ABL for management of CRB can potentially decrease the need for catheter removal, thus salvaging vascular access sites.